Literature DB >> 18790786

Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells.

Fan Fan1, Michael J Gray, Nikolaos A Dallas, Anthony D Yang, George Van Buren, E Ramsay Camp, Lee M Ellis.   

Abstract

Vascular endothelial growth factor (VEGF) is induced by stress. We determined whether chemotherapy (genotoxic stress) could induce expression of VEGF and VEGF receptors (VEGFR) in human colorectal cancer cells. The colorectal cancer cell lines HT29, RKO, and HCT116 were acutely exposed to increasing doses of oxaliplatin or 5-fluorouracil for 2, 6, and 24 h in vitro. Expression of VEGF ligand family members, VEGFRs, and signaling intermediates was determined by reverse transcription-PCR and Northern and Western blotting. The effect of oxaliplatin on VEGF-A transcriptional activity was determined by promoter assays. Acute exposure of human colorectal cancer cells to oxaliplatin led to a marked induction of VEGF-A mRNA and protein, whereas 5-fluorouracil alone or when added to oxaliplatin did not cause a further increase in VEGF levels. VEGF-A promoter activity was induced by oxaliplatin exposure. Expression of VEGF-C, placental growth factor, VEGFR-1, and neuropilin-1 levels were also increased when cells were treated with oxaliplatin. Oxaliplatin led to an increase in Akt and Src activation in HT29 cells. In contrast, Akt activation did not change in RKO cells whereas phospho-Src and phospho-p44/42 mitogen-activated protein kinase was dramatic increased by oxaliplatin. Inhibition of Akt or Src activation with wortmannin or PP2 blocked induction of VEGF-A by oxaliplatin in HT29 or RKO cells, respectively. VEGFRs may reflect the adaptive stress responses by which tumor cells attempt to protect themselves from genotoxic stress. Neutralization of prosurvival responses with anti-VEGF therapy might explain, in part, some of the beneficial effects of anti-VEGF therapy when added to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790786      PMCID: PMC2581833          DOI: 10.1158/1535-7163.MCT-08-0615

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  24 in total

1.  Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells.

Authors:  Q Shi; X Le; B Wang; J L Abbruzzese; Q Xiong; Y He; K Xie
Journal:  Oncogene       Date:  2001-06-21       Impact factor: 9.867

2.  Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway.

Authors:  Y D Jung; W Liu; N Reinmuth; S A Ahmad; F Fan; G E Gallick; L M Ellis
Journal:  Angiogenesis       Date:  2001       Impact factor: 9.596

3.  Coexpression of ephrin-Bs and their receptors in colon carcinoma.

Authors:  Wenbiao Liu; Syed A Ahmad; Young D Jung; Niels Reinmuth; Fan Fan; Corazon D Bucana; Lee M Ellis
Journal:  Cancer       Date:  2002-02-15       Impact factor: 6.860

4.  Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy.

Authors:  Dina Chelouche Lev; Maribelis Ruiz; Lisa Mills; Eric C McGary; Janet E Price; Menashe Bar-Eli
Journal:  Mol Cancer Ther       Date:  2003-08       Impact factor: 6.261

5.  UV induces VEGF through a TNF-alpha independent pathway.

Authors:  Maria G Kosmadaki; Mina Yaar; Bennett L Arble; Barbara A Gilchrest
Journal:  FASEB J       Date:  2003-01-22       Impact factor: 5.191

6.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

7.  Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.

Authors:  Dina Chelouche Lev; Amir Onn; Vladislava O Melinkova; Claudia Miller; Valerie Stone; Maribelis Ruiz; Eric C McGary; Honnavara N Ananthaswamy; Janet E Price; Menashe Bar-Eli
Journal:  J Clin Oncol       Date:  2004-05-03       Impact factor: 44.544

8.  Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis.

Authors:  D Shweiki; M Neeman; A Itin; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

9.  Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.

Authors:  Michael J Gray; George Van Buren; Nikolaos A Dallas; Ling Xia; Xuemei Wang; Anthony D Yang; Ray J Somcio; Yvonne G Lin; Sherry Lim; Fan Fan; Lingegowda S Mangala; Thiruvengadam Arumugam; Craig D Logsdon; Gabriel Lopez-Berestein; Anil K Sood; Lee M Ellis
Journal:  J Natl Cancer Inst       Date:  2008-01-08       Impact factor: 13.506

10.  Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids.

Authors:  Richard C Bates; Jeffrey D Goldsmith; Robin E Bachelder; Courtney Brown; Masabumi Shibuya; Peter Oettgen; Arthur M Mercurio
Journal:  Curr Biol       Date:  2003-09-30       Impact factor: 10.834

View more
  11 in total

1.  Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.

Authors:  Meriam Ayadi; Anaïs Bouygues; Djamila Ouaret; Nathalie Ferrand; Salem Chouaib; Jean-Paul Thiery; Christian Muchardt; Michèle Sabbah; Annette K Larsen
Journal:  Oncotarget       Date:  2015-07-30

2.  Deficiency of gap junction composed of connexin43 contributes to oxaliplatin resistance in colon cancer cells.

Authors:  Min Su; Qi Zhang
Journal:  Oncol Lett       Date:  2017-07-18       Impact factor: 2.967

3.  Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.

Authors:  Christopher J Morrow; Mohammad Ghattas; Christopher Smith; Heinz Bönisch; Richard A Bryce; D Mark Hickinson; Tim P Green; Caroline Dive
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

4.  Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.

Authors:  Yan Li; Xin-Yue Liang; Yi-Qi Yue; Lei Sheng; Ji-Kai Liu; Zhan-Yu Wang; Gang Chen
Journal:  Tumour Biol       Date:  2015-11-30

5.  TNFR-1 on tumor cells contributes to the sensitivity of fibrosarcoma to chemotherapy.

Authors:  Jingjing Deng; Xiaopu Zhao; Lijie Rong; Xiao Li; Xiaoman Liu; Zhihai Qin
Journal:  Protein Cell       Date:  2013-04-30       Impact factor: 14.870

6.  Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.

Authors:  F Fan; S Samuel; P Gaur; J Lu; N A Dallas; L Xia; D Bose; V Ramachandran; L M Ellis
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

7.  Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck.

Authors:  Sandra Schmitz; Denis Rommel; Nicolas Michoux; Renaud Lhommel; François-Xavier Hanin; Thierry Duprez; Jean-Pascal Machiels
Journal:  Radiol Oncol       Date:  2015-03-03       Impact factor: 2.991

8.  The sonic hedgehog signaling pathway stimulates anaplastic thyroid cancer cell motility and invasiveness by activating Akt and c-Met.

Authors:  Ashley J Williamson; Michelle E Doscas; Jin Ye; Katherine B Heiden; Mingzhao Xing; Yi Li; Richard A Prinz; Xiulong Xu
Journal:  Oncotarget       Date:  2016-03-01

9.  Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy.

Authors:  Jens Sperling; David Brandhorst; Thilo Schäfer; Christian Ziemann; Anna Benz-Weißer; Claudia Scheuer; Otto Kollmar; Martin K Schilling; Michael D Menger
Journal:  Clin Exp Metastasis       Date:  2012-11-27       Impact factor: 5.150

10.  Loss of CAR promotes migration and proliferation of HaCaT cells, and accelerates wound healing in rats via Src-p38 MAPK pathway.

Authors:  Linlin Su; Lanqing Fu; Xiaodong Li; Yue Zhang; Zhenzhen Li; Xue Wu; Yan Li; Xiaozhi Bai; Dahai Hu
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.